Related Experiment Videos
Agitation in dementia: Evidence-based consensus recommendations
Ying-Yu Chen1,2, Chien-Shu Tai1,3, Hsiu-Han Wen2
1Nursing Department, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Journal of the Chinese Medical Association : JCMA
|August 7, 2026
Summary
Person-centered approaches (PCAs) and non-pharmacological interventions are effective for managing agitation in dementia. Individualized, PCA-guided strategies, including music therapy and tailored activities, offer the best foundation for care.
Area of Science:
- Gerontology
- Psychiatry
- Evidence-based practice
Background:
- Agitation is a significant behavioral symptom in dementia, increasing caregiver burden and healthcare costs.
- Psychotropic medications have limited efficacy and notable adverse effects, necessitating alternative strategies.
Purpose of the Study:
- To evaluate the effectiveness of person-centered approaches (PCAs) and non-pharmacological interventions for dementia-related agitation.
- To synthesize evidence on interventions and assess their quality using the GRADE framework.
Main Methods:
- Comprehensive literature search of systematic reviews, meta-analyses, and RCTs on PCAs and non-pharmacological interventions for agitation in dementia.
- Quality assessment and strength of recommendations using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) framework.
Main Results:
- Moderate-quality evidence supports massage/touch therapy, individualized music therapy, tailored activities, and multicomponent interventions.
- Sensory-based approaches like aromatherapy and Snoezelen showed inconsistent or low-quality evidence.
- PCA implementation and need-driven assessments enhance intervention effectiveness and quality of life.
Conclusions:
- PCA-guided, multifaceted non-pharmacological interventions are the preferred approach for managing dementia agitation.
- Individualized strategies, preceded by systematic PCA assessments, yield the most significant benefits.
- Future research should focus on optimizing implementation through training, collaboration, and technology.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...